The management of acute venous thromboembolism in clinical practice
Key result
Real-world management of acute venous thromboembolism in 3,455 European patients predominantly involved initial therapy with heparin (73.2%), vitamin K antagonists (48.7%), and DOACs (24.5%).
Population
3,455 consecutive patients with acute venous thromboembolism, mean age 60.8 ± 17.0 years, 53.0% male, across…
Design
Cohort
Follow-up
12 months
Authors
Discussion
Loading...
Member takes
Implication
Real-world European VTE patterns inform but should not change practice; leaves open comparative effectiveness of DOAC uptake.
Study Design
Type
Observational (n=3,455)
Multicenter
Yes
Structured PICO
P
Population
3,455 consecutive patients with acute venous thromboembolism across seven European countries, followed for 12 months.
E
Exposure
Real-world management of acute VTE (including heparin, vitamin K antagonists, and DOACs)
O
Outcome
Epidemiology, management, and outcomes of VTE
The PREFER in VTE registry provides contemporary real-world insights into the baseline characteristics, management patterns, and outcomes of patients with acute VTE in Europe.
Cite This Study
Cohen et al. (2017) conducted an observational in Acute venous thromboembolism (n=3,455). Real-world management of acute VTE was evaluated. Real-world management of acute venous thromboembolism in 3,455 European patients predominantly involved initial therapy with heparin (73.2%), vitamin K antagonists (48.7%), and DOACs (24.5%).